aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
miércoles, 25 de abril de 2018
Press Announcements > FDA authorizes new use of test, first to identify the emerging pathogen Candida auris
Learn more about medical countermeasures (MCMs)—or help others learn—with our new infographic(PDF, 251 KB).
Image: (part of infographic) Medical countermeasures, or MCMs, are FDA-regulated products that may be used in a public health emergency stemming from a terrorist attack with or accidental release of a biological, chemical, or radiological/nuclear agent, or a naturally occurring emerging infectious disease. Full text description of entire infographic.
FDA authorizes new use of test
First to identify the emerging pathogen Candida auris
On April 20, 2018, FDA authorized the first test to identify the emerging pathogen Candida auris (C. auris), which can cause serious infections in hospitalized patients. C. auris is a yeast that can cause serious infections in hospitalized patients (e.g., bloodstream infections) and is frequently resistant to multiple antifungal drugs used to treat Candida infections. “Although mass spectrometry technology has been a powerful scientific tool since the 1980s, it is only within that the last five years that it has been effectively used for the identification of microbiological organisms and is now a widely recognized standard of practice for clinical laboratories,” said Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health (CDRH).
“The FDA has confidence in this technology and recognizes the need to rapidly address outbreaks both for C. auris and for other pathogenic microorganisms to help protect Americans through the recognition and identification of emerging infectious pathogens.”
Reminder: Laboratory personnel using Zika diagnostic assays under EUA are encouraged to report performance concerns directly to FDA at CDRH-EUA-Reporting@fda.hhs.gov, in addition to reporting concerns to the manufacturer.
Learn why diversity in clinical research is important by listening to FDA Office of Minority Health's new podcast (video, 17 minutes) featuring U.S. Army veterans discussing clinical trials. (April 2018)
From CDC - CDC released its 10th annual preparedness report, the Public Health Preparedness and Response 2018 National Snapshot. The Snapshot highlights preparedness activities and investments at the federal, state, and local levels, and features stories that demonstrate the impact of these activities. (April 16, 2018)
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||